| 초록 |
Background: The aim of the present study therefore was to determine whether dietary riboflavin intake is associated with chronic kidney disease (CKD) and/or metabolic disturbances in the general population.
Patients and Methods: Overall, 47,912 participants were included in this study. Participants were divided into 4 groups according to their dietary riboflavin intake quartile: the first quartile (Q1), second quartile (Q2), third quartile (Q3), and fourth quartile (Q4).
Results: The proportion of participants who were men, the high-density lipoprotein cholesterol level, and the estimated glomerular filtration rate increased from the Q1 to the Q4. In contrast, the prevalence of diabetes mellitus, hypertension, non-smoking status, non-heavy alcohol consumption, metabolic syndrome (MS), and CKD decreased from the Q1 to the Q4. In univariate analysis, compared with participants in the Q4, those in the Q1, Q2, and Q3 had a 1.906-fold, 1.361-fold, and 1.066-fold increased risk of MS, respectively; a 3.401-fold, 1.802-fold, and 1.381-fold increased risk of CKD, respectively; and a 3.231-fold, 1.962-fold, and 1.450-fold increased risk of cardiovascular disease (CVD), respectively. The same trend was seen also in multivariate analysis.
Conclusion: Low dietary riboflavin intake is associated with the prevalence of MS, CKD, and CVD. Adequate riboflavin supplements may help prevent the development of MS, CKD, and CVD in patients with suboptimal riboflavin intake. |